A significantly higher percentage of breast cancer patients having elevated ITGA5 protein levels in primary tumors were DTC-positive (p = 0.039), compared to that observed for patients with low ITGA5 levels in primary tumors (Fig. 1F and Table S2). This evidence concerns the gene ITGA5 and breast carcinoma.